Top 10 Defensive Stocks to Keep on Your Radar in Volatile Markets

Synopsis: Defensive stocks belong to the FMCG, retail, beverages, and pharmaceutical sectors, which provide essential products and medicines. They tend to remain stable during market volatility due to consistent demand and steady business performance.

Defensive stocks usually come from sectors that stay stable even when the market is volatile. These include consumer goods, healthcare, utilities, pharmaceuticals, and essential services because people always need basic products like food, medicine, electricity, and daily-use items. 

Telecom and insurance sectors are also considered defensive since customers continue to use phone services and financial protection in all economic conditions. Energy and FMCG (fast-moving consumer goods) companies often remain steady because demand does not fall much. These sectors are generally safer during uncertain markets because their businesses are less affected by economic ups and downs, and they usually provide steady earnings and stable growth over time. Here are 10 defensive stocks to keep on your radar in a volatile market

ITC Limited

With a market capitalization of Rs. 3,93,793.68 crore, the shares of ITC Limited were currently trading at Rs. 314.30 per equity share, down nearly 0.16 percent from its previous day’s close price of Rs. 314.80. 

ITC Limited was founded in 1910 and is an Indian diversified conglomerate headquartered in Kolkata, West Bengal. It operates across multiple sectors, including fast-moving consumer goods (FMCG), hotels, paperboards and packaging, agribusiness, and information technology. Known for its strong brand portfolio and sustainability initiatives, ITC is among India’s most valuable corporations.

Coming into financial highlights, ITC Limited’s revenue has increased from Rs. 18,790 crore in Q3 FY25 to Rs. 20,047 crore in Q3 FY26, which has grown by 6.69 percent. The net profit has also increased from Rs. 5,013 crore in Q3 FY25 to Rs. 5,018 crore in Q3 FY26.

Hindustan Unilever Limited

With a market capitalization of Rs. 5,42,696.84 crore, the shares of Hindustan Unilever Limited were currently trading at Rs. 2308.05 per equity share, down nearly 0.51 percent from its previous day’s close price of Rs. 2319.80. 

Hindustan Unilever Limited (HUL) was founded in 1933 and is India’s largest fast-moving consumer goods (FMCG) company, offering products across categories like home care, beauty, personal care, and food. A subsidiary of the global giant Unilever, it has been central to India’s consumer market for over 90 years.

Coming into financial highlights, Hindustan Unilever Limited’s revenue has increased from Rs. 15,556 crore in Q3 FY25 to Rs. 16,441 crore in Q3 FY26, which has grown by 5.69 percent. The net profit has also grown by 120.91 percent from Rs. 2,989 crore in Q3 FY25 to Rs. 6,603 crore in Q3 FY26.

Nestle India Limited

With a market capitalization of Rs. 2,42,196.28 crore, the shares of Nestle India Limited were currently trading at Rs. 1256.00 per equity share, down nearly 1.81 percent from its previous day’s close price of Rs. 1279.10. 

Nestlé India Limited was established in 1959 and is headquartered in New Delhi, and is a publicly listed subsidiary of Nestlé S.A., engaged in manufacturing and marketing food and beverage products across India. It is among India’s leading fast-moving consumer goods (FMCG) companies, known for brands such as Maggi, Nescafé, and KitKat. 

Coming into financial highlights, Nestle India Limited’s revenue has increased from Rs. 4,780 crore in Q3 FY25 to Rs. 5,667 crore in Q3 FY26, which has grown by 18.56 percent. The net profit has also grown by 46.26 percent from Rs. 696 crore in Q3 FY25 to Rs. 1,018 crore in Q3 FY26.

Varun Beverages Limited

With a market capitalization of Rs. 1,45,430.06 crore, the shares of Varun Beverages Limited were currently trading at Rs. 430.00 per equity share, down nearly 3.43 percent from its previous day’s close price of Rs. 445.25.

Varun Beverages Limited (VBL) was founded in 1995 and is an Indian multinational beverage company and one of PepsiCo’s largest franchise bottlers globally, responsible for manufacturing, bottling, and distributing its soft drinks, packaged water, and non-carbonated beverages across India and multiple international markets.

Coming into financial highlights, Varun Beverages Limited’s revenue has increased from Rs. 3,689 crore in Q3 FY25 to Rs. 4,204 crore in Q3 FY26, which has grown by 13.96 percent. The net profit has also grown by 32.65 percent from Rs. 196 crore in Q3 FY25 to Rs. 260 crore in Q3 FY26.

Avenue Supermarts Limited

With a market capitalization of Rs. 2,45,993.37 crore, the shares of Avenue Supermarts Limited were currently trading at Rs. 3780.25 per equity share, down nearly 0.54 percent from its previous day’s close price of Rs. 3800.75. 

Avenue Supermarts Limited was founded in 2000 by investor Radhakishan S. Damani and is an Indian retail company that operates the nationwide supermarket chain DMart. It is among India’s leading organized retail groups, known for value-focused shopping across groceries, household, and apparel categories. The company’s disciplined cost structure and owned-store model have made it a benchmark in India’s value retail segment.

Coming into financial highlights, Avenue Supermarts Limited’s revenue has increased from Rs. 15,973 crore in Q3 FY25 to Rs. 18,101 crore in Q3 FY26, which has grown by 13.32 percent. The net profit has also grown by 18.23 percent from Rs. 724 crore in Q3 FY25 to Rs. 856 crore in Q3 FY26.

Sun Pharmaceutical Industries Limited

With a market capitalization of Rs. 4,18,698.08 crore, the shares of Sun Pharmaceutical Industries Limited were currently trading at Rs. 1745.10 per equity share, down nearly 0.43 percent from its previous day’s close price of Rs. 1752.70. 

Sun Pharmaceutical Industries Limited (Sun Pharma) was founded in 1983 by Dilip Shanghvi and is an Indian multinational pharmaceutical company specializing in branded and generic formulations, specialty medicines, and active pharmaceutical ingredients (APIs). It is India’s largest pharmaceutical company and among the top five specialty generics manufacturers globally.

Coming into financial highlights, Sun Pharmaceutical Industries Limited’s revenue has increased from Rs. 13,675 crore in Q3 FY25 to Rs. 15,521 crore in Q3 FY26, which has grown by 13.50 percent. The net profit has also grown by 16.07 percent from Rs. 2,913 crore in Q3 FY25 to Rs. 3,381 crore in Q3 FY26.

Cipla Limited

With a market capitalization of Rs. 1,08,283.00 crore, the shares of Cipla Limited were currently trading at Rs. 1342.00 per equity share, down nearly 0.73 percent from its previous day’s close price of Rs. 1351.85. 

Cipla Limited was established in 1935 by Dr. Khwaja Abdul Hamied, a leading Indian multinational pharmaceutical company. It has become one of India’s most prominent healthcare firms, known for affordable, high-quality medicines. Cipla’s mission, “Caring for Life,” reflects its humanitarian approach to global healthcare access.

Coming into financial highlights, Cipla Limited’s revenue has increased from Rs. 7,073 crore in Q3 FY25 to Rs. 7,074 crore in Q3 FY26, which has grown by 0.01 percent. The net profit has decreased by 57.21 percent from Rs. 1,575 crore in Q3 FY25 to Rs. 674 crore in Q3 FY26.

Divis Laboratories Limited

With a market capitalization of Rs. 1,67,285.03 crore, the shares of Divis Laboratories Limited were currently trading at Rs. 6314.50 per equity share, down nearly 1.39 percent from its previous day’s close price of Rs. 6403.35. 

Divis Laboratories Limited was founded on October 12, 1990, and is an Indian multinational pharmaceutical company specializing in active pharmaceutical ingredients (APIs), intermediates, and nutraceutical ingredients, headquartered in Hyderabad, Telangana. It is regarded as one of the world’s largest generic API manufacturers and a key custom synthesis partner for major global innovator pharma companies.

Coming into financial highlights, Divis Laboratories Limited’s revenue has increased from Rs. 2,319 crore in Q3 FY25 to Rs. 2,604 crore in Q3 FY26, which has grown by 12.29 percent. The net profit has decreased by 1.02 percent from Rs. 589 crore in Q3 FY25 to Rs. 583 crore in Q3 FY26.

Dr Reddys Laboratories Limited

With a market capitalization of Rs. 1,07,355.11 crore, the shares of Dr Reddys Laboratories Limited were currently trading at Rs. 1286.30 per equity share, down nearly 0.64 percent from its previous day’s close price of Rs. 1294.65. 

Dr. Reddy’s Laboratories Limited was founded in 1984 by scientist and entrepreneur Dr. Kallam Anji Reddy and is a multinational pharmaceutical company headquartered in Hyderabad, India. It is one of India’s largest drug manufacturers, recognized for affordable generics, biosimilars, and active pharmaceutical ingredients (APIs) supplied to markets worldwide.

Coming into financial highlights, Dr Reddys Laboratories Limited’s revenue has increased from Rs. 8,381 crore in Q3 FY25 to Rs. 8,753 crore in Q3 FY26, which has grown by 4.44 percent. The net profit has decreased by 15.24 percent from Rs. 1,404 crore in Q3 FY25 to Rs. 1,190 crore in Q3 FY26.

Natco Pharma Limited

With a market capitalization of Rs. 17,682.62 crore, the shares of Natco Pharma Limited were currently trading at Rs. 987.25 per equity share, rising nearly 3.23 percent from its previous day’s close price of Rs. 956.40. 

Natco Pharma Limited was founded in 1981 and is an Indian multinational pharmaceutical company known for producing affordable generic medicines and specialty pharmaceuticals. It plays a significant role in oncology, hepatitis C, and cardiovascular treatments, with a focus on cost-effective therapies and active pharmaceutical ingredients (APIs).

Coming into financial highlights, Natco Pharma Limited’s revenue has increased from Rs. 475 crore in Q3 FY25 to Rs. 647 crore in Q3 FY26, which has grown by 36.21 percent. The net profit has increased by 14.39 percent from Rs. 132 crore in Q3 FY25 to Rs. 151 crore in Q3 FY26.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Top 10 Defensive Stocks to Keep on Your Radar in Volatile Markets appeared first on Trade Brains.